Page 1

Spermosens AB ( publ ) INTERIM REPORT APRIL – JUNE 2026 In the second quarter of 2026 , we saw recruitment into its Generation 3 clinical validation study exceed expectations , broadened partnership discussions across markets , and secured working capital 1 APRIL - 30 JUNE 2026 SIGNIFICANT EVENTS DURING THE INTERIM PERIOD 8 April , 2026 Spermosens completes development of JUNO - Checked Generation 3 and initiates clinical validation study 29 April , 2026 Spermosens reports JUNO - Checked Generation 3 clinical validation study on track 7 May , 2026 Spermosens AB ( publ ) INTERIM REPORT JANUARY - MARCH 2026 7 May , 2026 Spermosens secures SEK 4.85 million capital facility to support development and commercialization 18 May , 2026 28 May , 2026 18 June , 2026 NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB ( publ ) Spermosens publishes annual report for the financial year 2025 Bulletin from Annual General Meeting in Spermosens AB ( publ ) SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD 1 July , 2026 Spermosens provides an update on the Generation 3 clinical study 21 July , 2026 Spermosens calls SEK 4.85 million under previously announced Capital Facility 6 August , 2026 Spermosens raises approx . SEK 4.85m in directed issue and calls EGM 6 August , 2026 Notice of Extraordinary General Meeting in Spermosens AB ( publ ) 1 Interim report April - June , 2026 | Spermosens AB ( publ ) , org nr 559179-0380